Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Lanier R. Tanner"'
Autor:
Albiruni Ryan Abdul Razak, Stephanie Baker, Herbert H. Loong, Sharon Friedlander, Joel Ellis, Mrinal M. Gounder, William D. Tap, Robert O. Carlson, Joseph P. Erinjeri, Alona Zer, Michael Kauffman, Mercedes M. Condy, Mark A. Dickson, Sharon Shacham, Gary K. Schwartz, Francis H. Jasmine, Samer Salah, Tami Rashal, Lanier R. Tanner, Sandra P. D'Angelo, Kjirsten Nyquist-Schultz, Abha A. Gupta, Thaddeus J. Unger, Mary Louise Keohan, Jean-Richard Saint-Martin
Publikováno v:
Journal of Clinical Oncology. 34:3166-3174
Purpose We evaluated the pharmacokinetics (PKs), pharmacodynamics, safety, and efficacy of selinexor, an oral selective inhibitor of nuclear export compound, in patients with advanced soft tissue or bone sarcoma with progressive disease. Patients and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::78d10dae3ea1fa1f76b1fecc4dcf97bd
https://doi.org/10.1200/jco.2016.67.6346
https://doi.org/10.1200/jco.2016.67.6346
Autor:
Robert W. Carlson, Alona Zer, Sharon Shacham, Tami Rashal, Lanier R. Tanner, Ping Chi, Sandra P. D'Angelo, Jean-Richard Saint-Martin, Abha A. Gupta, Mary Louise Keohan, Albiruni Ryan Abdul Razak, Mark A. Dickson, William D. Tap, Dilara McCauley, Mrinal M. Gounder, Mansoor Raza Mirza, Theresa Konen, Gary K. Schwartz, Michael Kauffman, Tracey Marshall
Publikováno v:
Journal of Clinical Oncology. 33:10569-10569
10569 Background: Sarcomas are a heterogeneous group of malignancies with diverse genetic abnormalities. Selinexor is a first-in-class, oral, inhibitor of XPO1, (nuclear exportin protein 1) with potent anti-tumor activity in multiple sarcoma cell lin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac0707ad610387e8bea0f8b9ca25ceca
https://doi.org/10.1200/jco.2015.33.15_suppl.10569
https://doi.org/10.1200/jco.2015.33.15_suppl.10569
Autor:
Dilara McCauley, Tami Rashal, Herbert H. Loong, Lanier R. Tanner, Eran Shacham, Yosef Landesman, Mansoor Raza Mirza, Albiruni Ryan Abdul Razak, Mrinal M. Gounder, Sharon Tamir, Sasha Rebello, Stephanie Baker, Kjirsten Nyquist-Schultz, Michael Kauffman, Sharon Shacham, Yelena Ustoyev, Jean-Richard Saint-Martin, Gary K. Schwartz, Tracey Marshall, Sharon Friedlander
Publikováno v:
ResearcherID
10587 Background: Sarcomas are heterogeneous diseases with multiple genetic abnormalities. XPO1 inhibition can restore the activity of multiple tumor suppressor proteins (TSP) including p53, Rb, an...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef5f2038a11784f45eb20eac1de5e827
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000358613204720&KeyUID=WOS:000358613204720
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000358613204720&KeyUID=WOS:000358613204720
Autor:
Rita Elena Morales, Nian Wu, Li-Xuan Qin, Robert G. Maki, Mary Louise Keohan, Gary K. Schwartz, Lanier R. Tanner, Mark A. Dickson, Sandra P. D'Angelo, Mercedes M. Condy, Yelena Ustoyev, Mrinal M. Gounder, S. Percy Ivy, William D. Tap, Richard D. Carvajal, Joseph P. Erinjeri, Naoko Takebe
Publikováno v:
Web of Science
10004 Background: Aberrant Hedgehog and Notch signaling is seen in sarcoma and anti-tumor activity is enhanced by inhibiting both pathways. This first in man Phase Ib study evaluated safety and efficacy of the combination of GDC-0449 (G), a smoothene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eba28f141a9fb588ac2ec75dff328501
https://publons.com/wos-op/publon/30657625/
https://publons.com/wos-op/publon/30657625/